Impact of Race/Ethnicity on Platelet Function

Healthy people and coronary heart disease patients taking aspirin or aspirin and clopidogrel or prasugrel

Inclusion Criteria: Each subject must fulfill the following criteria in order to be included in the study.

• The subject must be capable of understanding the nature of the study and executing an informed consent document.
• The subject must be aged 19 years or older.
• For healthy subjects, the subject must deny taking any medications that affect platelet function for at least 7 days before blood collection.
• For diseased patients, subjects with documented CAD are eligible to participate if they have been treated with antiplatelet therapy of aspirin (81 to 325 mg/day) with and without clopidogrel (75 mg/day) or another P2Y12 antagonist for at least one month.

Exclusion Criteria: For healthy volunteers, subjects who fulfill one or more of the following criteria will be excluded from the study.

• taking medications for chronic cardiovascular diseases.
• illnesses requiring hospitalization or surgery within the last three months.
• history of drug or alcohol abuse.
• history of recent anemia or thrombocytopenia.
• history of excessive bleeding or thrombosis.
• pregnancy.

For coronary heart disease subjects, subjects who fulfill one or more of the following criteria will be excluded from the study.

• illnesses requiring hospitalization or surgery within the last one month.
• history of drug or alcohol abuse.
• history of recent anemia or thrombocytopenia.
• pregnancy.
• recent bleeding diathesis
• malignancy
• renal insufficiency
• liver dysfunction
• treatment with warfarin or glycoprotein (GP) IIb/IIIa antagonists during the preceding 14 days